Clinical Trials Browser

Familial ependymoma, Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Central Nervous System Neoplasms, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor

NCT03277469 2026-04-22

Optimizing Brachytherapy Application and Delivery With MRI Guidance for Gynecologic Cancer

Phase NA Active not recruiting

49 enrolled

Gynecologic

Gynecologic Cancer

NCT03295981 2026-04-22

Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone

Phase 3 Recruiting

120 enrolled

Giant Cell Tumor of Bone

NCT03303846 2026-04-22

Combined Breast MRI and Biomarker Strategies in Identifying High-risk Breast Cancer Patients

Phase NA Active not recruiting

344 enrolled

Healthy Subject

NCT03395197 2026-04-22

TALAPRO-2

Phase 3 Active not recruiting

1,054 enrolled 21 charts 2 FDA

mCRPC

NCT03436654 2026-04-22

Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma

Phase 2 Active not recruiting

102 enrolled

Genitourinary

Prostatic Neoplasms

NCT03481114 2026-04-22

REPAINT

Phase 2 Completed

55 enrolled 19 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03523975 2026-04-22

Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma

Phase 1/2 Recruiting

28 enrolled

Lymphoid

Lymphoma, Mantle-Cell

NCT03625323 2026-04-22

TACTI-002

Phase 2 Completed

187 enrolled 13 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT03736889 2026-04-22

Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors

Phase 2 Recruiting

200 enrolled

Other solid neoplasm

MSI-H/dMMR Solid Tumors

NCT03785288 2026-04-22

Vaginal Cuff Brachytherapy Fractionation Study

Phase 3 Recruiting

258 enrolled

Gynecologic

Endometrial Neoplasms

NCT03823534 2026-04-22

Post-Op Pain Control for Prophylactic Intramedullary Nailing.

Phase 3 Recruiting

60 enrolled

LymphoidPlasma cell

Lymphoma, Multiple Myeloma, Pain, Pain, Postoperative

NCT03866382 2026-04-22

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Phase 2 Recruiting

314 enrolled

Genitourinary

Urachal adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Penile Neoplasms, Prostatic Neoplasms, Urethral Neoplasms, Urogenital Neoplasms

NCT03970447 2026-04-22

GBM AGILE

Phase 2/3 Recruiting

2,250 enrolled

CNS

Glioblastoma, Recurrence

NCT03981146 2026-04-22

ANICCA

Phase 2 Completed

35 enrolled 15 charts

Gastrointestinal

Colorectal Neoplasms

NCT04049331 2026-04-22

Testosterone Replacement in Male Cancer Survivors With Fatigue and Low Testosterone

Phase 2 Active not recruiting

240 enrolled

Eunuchism, Hypogonadism, Fatigue Syndrome, Chronic

NCT04080804 2026-04-22

Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer

Phase 2 Active not recruiting

80 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT04082520 2026-04-22

Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy

Phase 2 Recruiting

42 enrolled

CNS

Meningioma

NCT04123366 2026-04-22

MK-7339-007

Phase 2 Active not recruiting

300 enrolled

Other solid neoplasm

Solid Tumors

NCT04192981 2026-04-22

GDC-0084 With Radiation Therapy for People With PIK3CA-Mutated Solid Tumor Brain Metastases or Leptomeningeal Metastases

Phase 1 Active not recruiting

21 enrolled

CNS

Brain Neoplasms, Meningeal Carcinomatosis

NCT04246177 2026-04-22

LEAP-012

Phase 3 Completed

479 enrolled

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Hepatocellular

NCT04267848 2026-04-22

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Phase 3 Recruiting

1,210 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04269902 2026-04-22

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

Phase 3 Recruiting

247 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04349436 2026-04-22

ARTACUS

Phase 1/2 Active not recruiting

69 enrolled

Dermatologic

Carcinoma, Carcinoma, Basal Cell, Neoplasms, Skin Neoplasms, Carcinoma, Merkel Cell

NCT04396860 2026-04-22

Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma

Phase 2/3 Completed

159 enrolled 17 charts

Sarcoma

Gliosarcoma

NCT04402788 2026-04-22

Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial

Phase 2/3 Recruiting

138 enrolled

Extensive Stage Lung Small Cell Carcinoma

NCT04452305 2026-04-22

Spermatogonial Stem Cell (SSC) Transplant and Testicular Tissue Grafting

Phase NA Recruiting

10 enrolled

Autoimmune Diseases, Infertility, Male, Neoplasms

NCT04452955 2026-04-22

A Study to Assess Safety and Efficacy of PRL3-Zumab in Patients With Solid Tumors

Phase 2 Active not recruiting

51 enrolled

Tumor-Agnostic

Neoplasms

NCT04487080 2026-04-22

MARIPOSA

Phase 3 Active not recruiting

1,074 enrolled 13 charts 2 FDA

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04521686 2026-04-22

Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations

Phase 1 Active not recruiting

200 enrolled

BreastCNSDermatologicGastrointestinalGenitourinaryHead & NeckSarcoma

Breast Neoplasms, Chondrosarcoma, Colonic Neoplasms, Glioblastoma, Glioma, Melanoma, Prostatic Neoplasms, Thyroid Neoplasms, Central Nervous System Neoplasms, Cholangiocarcinoma

NCT04530552 2026-04-22

Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland

Phase 2 Active not recruiting

34 enrolled 11 charts

Genitourinary

Prostatic Neoplasms

NCT04595565 2026-04-22

SASCIA

Phase 3 Active not recruiting

1,332 enrolled

Breast

Triple Negative Breast Neoplasms

Clinical Trials

Open Versus Laparoscopically-assisted Esophagectomy for Cancer

Vandevol

VEGAS

METAPERF

Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer

Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL)

Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression

VISMONEO

Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer

Phase II High Dose Brachytherapy and Low Dose Rate Brachytherapy as Monotherapy in Localized Prostate Cancer

Testicular Tissue Cryopreservation for Fertility Preservation

Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma

Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia

CASPIAN

MYOPK

Pre-operative Treatment for Patients With Untreated Pancreatic Cancer

Chronic Convection Enhanced Delivery of Topotecan

18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer

Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)

Optimizing Brachytherapy Application and Delivery With MRI Guidance for Gynecologic Cancer

Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone

Combined Breast MRI and Biomarker Strategies in Identifying High-risk Breast Cancer Patients

TALAPRO-2

Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma

REPAINT

Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma

TACTI-002

Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors

Vaginal Cuff Brachytherapy Fractionation Study

Post-Op Pain Control for Prophylactic Intramedullary Nailing.

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

GBM AGILE

ANICCA

Testosterone Replacement in Male Cancer Survivors With Fatigue and Low Testosterone

Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer

Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy

MK-7339-007

GDC-0084 With Radiation Therapy for People With PIK3CA-Mutated Solid Tumor Brain Metastases or Leptomeningeal Metastases

LEAP-012

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

ARTACUS

Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma

Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial

Spermatogonial Stem Cell (SSC) Transplant and Testicular Tissue Grafting

A Study to Assess Safety and Efficacy of PRL3-Zumab in Patients With Solid Tumors

MARIPOSA

Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations

Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland

SASCIA